HOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today highlighted Nexalin’s rigorous peer-reviewed clinical research validating its proprietary neurostimulation
A 25-year study found an unexpected link between cheese and dementia
A major long-term study from Sweden found that middle-aged and older adults who ate more full-fat cheese and cream had a lower risk of developing dementia. While the results may sound encouraging, researchers emphasize that they should be interpreted with …
